silicristin | 935752-46-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: silicristin
• 英文别名: Silychristin；3,5,7-trihydroxy-2-[7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-3-hydroxymethyl-2,3-dihydro-benzofuran-5-yl]-chroman-4-one；Silychrystin；3,5,7-trihydroxy-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1-benzofuran-5-yl]-2,3-dihydrochromen-4-one
• CAS: 935752-46-8
• 化学式: C₂₅H₂₂O₁₀
• 分子量: 482.444
• InChiKey: BMLIIPOXVWESJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  166
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• Silibinin component for the treatment of hepatitis
  申请人：Madaus GmbH

  公开号：EP2392326B1

  公开（公告）日：2018-01-24
• SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS
  申请人：Rovati Lucio Claudio

  公开号：US20110182858A1

  公开（公告）日：2011-07-28

  The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin
• AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS
  申请人：Rovati Lucio Claudio

  公开号：US20120108825A1

  公开（公告）日：2012-05-03

  The invention relates to a method for the preparation of amorphous silibinin (or its synonyms: silybin or silibin) derived from a milk thistle fruit extract having an increased release rate and improved absorbability or bioavailability, and to the use of amorphous silibinin for the treatment or prevention of liver diseases, preferably for the treatment of viral hepatitis, e.g. hepatitis B or C, in particular in a patient who will undergo or has undergone liver transplantation. Preferably, the amorphous silibinin is adapted for oral administration.
• METHOD TO IDENTIFY COMPOUNDS ABLE TO BIND TO THE ROSSMANN FOLD OF C-TERMINAL-BINDING PROTEINS, IDENTIFIED COMPOUNDS AND MEDICAL USES THEREOF
  申请人：CONSIGLIO NAZIONALE DELLE RICERCHE

  公开号：US20170003275A1

  公开（公告）日：2017-01-05

  The invention refers to a method for identifying an anti-tumoral and/or anti-proliferative and/or an inhibitor of the fission machinery involved in mitotic Golgi partitioning and/or a molecule modulator of CtBP corepressor activity by testing their affinity binding for the Rossmann fold of C-terminal-binding proteins (CtBPs); to said identified molecules and to the use thereof as anti-proliferative and/or anti tumoral agents.